Saudi Arabia is set to elevate its drug production capabilities with the recent signing of four pivotal agreements, signaling a robust collaboration between the kingdom’s public and private sectors. The Local Content and Government Procurement Authority (LCGPA) signed these deals, for the localization of industry and knowledge transfer on Monday. The agreements underscore the nation’s commitment to bolstering health and pharmaceutical security through cooperation and integration.
The financial impact of localizing drug production in Saudi Arabia is projected to exceed SAR250 million ($67 million) over a decade for each agreement. Moreover, the agreements solidify the sustainable partnership between the government and private sectors.
Drug production agreements
The agreements mark a milestone for Saudi Arabia in the localization of the pharmaceutical industry and the transfer of knowledge in drug production. The deals, rooted in the principle of cooperation, aim to enhance drug production, health, and pharmaceutical security. Moreover, they seek to foster development within Saudi Arabia.
Saudi Arabia’s LCGPA signed agreements with Jamjoom Pharma and American company MSD for the production of the drug sitagliptin phosphate. It is a medication vital for treating type 2 diabetes. This partnership aligns with the broader goal of achieving self-sufficiency and advancing pharmaceutical capabilities in the Kingdom.
LCGPA also signed agreements with Aja Pharma and SAJA Pharmaceutical Co. to manufacture ticagrelor. It is an antiplatelet medication that reduces the risk of blood clots.
Strategic efforts
This collaboration is not an isolated event. It aligns with the kingdom’s broader efforts to enhance the business sector. In October 2023, the Saudi Authority for Industrial Cities and Technology Zones (MODON) took steps to promote national products. It signed agreements with the Saudi Export Development Authority and the LCGPA.
The MODON-LCGPA agreement focuses on integrating industrial cities to enhance local content and foster innovation. Hence, the objective is to establish incentive programs for industrial partners and agreements that contribute to the localization of industry and knowledge transfer.
Read: Future Health Summit: UAE leads booming global longevity market
Significance of local content
Local content plays a pivotal role in the development of non-oil sectors and the gross domestic product (GDP). The kingdom’s leadership has consistently taken steps to enhance and develop local content, recognizing its strategic importance. Therefore, the LCGPA remains steadfast in its dedication to developing it across all components of the Saudi economy. This commitment extends to improving government procurement processes. Moreover, it ensures alignment with national visions and contributes to the realization of development and financial goals.
The recent agreements signify a significant stride in Saudi Arabia’s pharmaceutical sector, promising not only enhanced drug production capabilities but also fostering a robust ecosystem of cooperation between the public and private sectors. As the Kingdom continues its commitment to economic development, these partnerships lay the groundwork for a self-sufficient and innovative pharmaceutical industry.
For more news on health, click here.
